ADC Therapeutics SA: Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. ADC Therapeutics SA is a commercial-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs), primarily commercializing ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is currently navigating a strategic reorganization to focus resources on ZYNLONTA expansion and its PSMA-targeting ADC pipeline.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenue | $19,248 | $18,839 | $40,099 | $41,872 |
| Net Loss | $(16,565) | $(56,646) | $(49,533) | $(95,248) |
| Loss Per Share (Diluted) | $(0.11) | $(0.50) | $(0.32) | $(0.86) |
| Cash and Equivalents | $219,107 | $264,560 | $219,107 | $264,560 |
| Operating Cash Flow (6M) | $(41,517) | $(80,421) | $(41,517) | $(80,421) |
| Total Debt (Current + Long-term) | $116,617 | $115,452 | $116,617 | $115,452 |
| Deferred Royalty Obligation | $320,628 | $333,579 | $320,628 | $333,579 |
Note: Debt figures include Senior Secured Term Loans. Deferred Royalty Obligation is a significant non-cash liability.
Material Changes vs. Prior Period
- Revenue: Total revenue for the six months ended June 30, 2026, decreased 4.2% to $40.1 million compared to $41.9 million in the prior year. This was driven by a 77.6% drop in license revenues and royalties (due to a one-time $5.0 million milestone in 2025), partially offset by a 9.0% increase in product revenues to $38.7 million.
- Net Loss: Net loss improved significantly, decreasing 48.0% to $49.5 million for the six months ended June 30, 2026, compared to $95.2 million in the prior year. This improvement was largely due to a $23.1 million gain in "Other, net" income.
- Operating Expenses: Total operating expenses decreased 20.7% to $90.8 million (6M 2026) from $114.5 million (6M 2025). Research and Development (R&D) expenses dropped 36.9% to $37.2 million, reflecting the completion of the 2025 Restructuring and discontinuation of early-stage programs.
- Unusual Items: The company recognized $16.6 million in income from the change in fair value of warrant obligations issued to HealthCare Royalty Management (HCR) and a $6.4 million cumulative catch-up adjustment related to the deferred royalty obligation.
Guidance, Outlook, and Risks
- Clinical Trial Updates:
- LOTIS-5: Topline data showed statistical significance for progression-free survival (PFS) but also a higher rate of Grade 5 (fatal) adverse events in the treatment arm compared to control. The FDA expressed "substantial concerns" regarding the benefit-risk profile, potentially impacting full approval for earlier lines of therapy. The company is assessing the regulatory path forward.
- LOTIS-7: Enrollment completed for the Phase 1b trial combining ZYNLONTA with glofitamab. The company plans to submit for Breakthrough Therapy designation.
- Restructuring: A new "2026 Restructuring" was announced in June 2026, targeting a 17% global workforce reduction to be completed by September 30, 2026. Costs of $2.7 million were accrued in Q2 2026.
- Liquidity: Management believes cash resources of $219.1 million are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring losses and may require additional capital.
- Risks: Key risks include the FDA's concerns over LOTIS-5 safety data, the potential withdrawal of accelerated approval for ZYNLONTA if clinical benefit is not verified, and the restrictive covenants associated with the HCR royalty financing and senior secured term loans.
Investor Verification Checklist
- Regulatory Status of LOTIS-5: Verify the specific outcome of the pre-sBLA meeting with the FDA and the company's definitive plan for seeking approval in earlier lines of therapy given the safety concerns.
- Deferred Royalty Obligation: Review the assumptions used for the $6.4 million catch-up adjustment and the long-term impact of the HCR agreement on future cash flows and acquisition attractiveness.
- Restructuring Execution: Monitor the completion of the 2026 workforce reduction and the associated cash outflows expected in Q3 2026.
- Revenue Sustainability: Assess the durability of the 9% product revenue growth given the competitive landscape and the potential impact of the LOTIS-5 safety profile on market perception.
- Debt Covenants: Confirm compliance with financial covenants under the Senior Secured Term Loan and the Amended HCR Agreement, particularly regarding liquidity and royalty payments.